Fed Governor Lisa Cook Warns Inflation Risks Remain as Rates Stay Steady 
Trump Signs Executive Order Threatening 25% Tariffs on Countries Trading With Iran 
Washington Post Publisher Will Lewis Steps Down After Layoffs 
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape 
Japanese Pharmaceutical Stocks Slide as TrumpRx.gov Launch Sparks Market Concerns 
Singapore Budget 2026 Set for Fiscal Prudence as Growth Remains Resilient 
Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
Russian Stocks End Mixed as MOEX Index Closes Flat Amid Commodity Strength 
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO 
South Korea’s Weak Won Struggles as Retail Investors Pour Money Into U.S. Stocks 
India–U.S. Interim Trade Pact Cuts Auto Tariffs but Leaves Tesla Out 
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links 
Trump Endorses Japan’s Sanae Takaichi Ahead of Crucial Election Amid Market and China Tensions 
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 
U.S. Stock Futures Slide as Tech Rout Deepens on Amazon Capex Shock 
Trump’s Inflation Claims Clash With Voters’ Cost-of-Living Reality 
Japanese beer and beverage maker Kirin is selling its China soft drinks joint venture to a Chinese investment fund, Plateau Consumer, for $994 million to enhance its pharmaceutical business.
The sale covers Kirin’s entire 40 percent stake in China Resources Kirin Beverages.
Established in 2011, China Resources Kirin Beverage had been expanding its business in China, making bottled water and bottled tea.
The move was part of its recent decision to review its investment portfolio, including foreign operations, under a management plan that runs through 2024. It comes shortly after Kirin decided to pull out of a joint venture brewery in Myanmar.
Kirin is focusing on certain areas, including pharmaceuticals and health science as well as food and beverages.
The Tokyo-based company has been streamlining its operations to focus on pharmaceutical projects like developing drugs for diseases that have no existing treatments and working on what it calls LC-Plasma to offer products that help maintain immune systems.
Kirin is among Japan’s top beer brands, and still has various global operations, including Four Roses Distillery in the U.S. and San Miguel Brewery in the Philippines.
.
